Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.61 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23949831 | 0.89 | P2RX7 (0.66) | P2RX7P2RY12JAK2EZH2KMT2A | |
| SCHEMBL23949833 | 0.86 | P2RX7 (0.66) | P2RX7P2RY12KMT2A | |
| SCHEMBL23949847 | 0.83 | P2RX7 (0.58) | P2RX7P2RY12 | |
| SCHEMBL23949982 | 0.81 | P2RX7 (0.65) | P2RX7P2RY12ALDH1A1 | |
| SCHEMBL23949830 | 0.80 | P2RX7 (0.45) | P2RX7P2RY12MEN1KMT2AALDH1A1 | |
| SCHEMBL23949829 | 0.80 | P2RX7 (0.46) | P2RX7P2RY12 | |
| SCHEMBL7217917 | 0.76 | LMNA (0.60) | P2RX7JAK2EZH2 | |
| SCHEMBL23949853 | 0.76 | P2RX7 (0.83) | P2RX7P2RY12JAK2MEN1KMT2A | |
| SCHEMBL21753383 | 0.76 | P2RX7 (1.00) | P2RX7P2RY12MEN1KMT2A | |
| SCHEMBL23949832 | 0.75 | P2RX7 (0.46) | P2RX7JAK2EZH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | P2RX1, P2RX3, P2RX5 | P2RX7 4/4885P2RY12 14/4885JAK2 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.